Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Eric D Donnenfeld & Ryan D Shojaei. (2019) Effect Of Intracameral Phenylephrine And Ketorolac 1.0%/0.3% On Intraoperative Pain And Opioid Use During Cataract Surgery. Clinical Ophthalmology 13, pages 2143-2150.
Read now
Read now
Rahul Reddy & Stephen Jae Kim. (2011) Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery. Clinical Ophthalmology 5, pages 751-758.
Read now
Read now
Xiao Jing Wang, Sze H Wong, Roshan Givergis & Emil W Chynn. (2011) Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK. Clinical Ophthalmology 5, pages 1451-1457.
Read now
Read now
Frank A. Bucci$suffix/text()$suffix/text() & L. David Waterbury. (2011) A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification. Current Medical Research and Opinion 27:12, pages 2235-2239.
Read now
Read now
Mayssa Attar, Rhett Schiffman, Lisa Borbridge, Quinn Farnes & Devin Welty. (2010) Ocular pharmacokinetics of 0.45% ketorolac tromethamine. Clinical Ophthalmology 4, pages 1403-1408.
Read now
Read now
Eliana B. Souto, Slavomira Doktorovova, Elisabet Gonzalez-Mira, Maria Antonia Egea & Maria Luisa Garcia. (2010) Feasibility of Lipid Nanoparticles for Ocular Delivery of Anti-Inflammatory Drugs. Current Eye Research 35:7, pages 537-552.
Read now
Read now
Helga P Sandoval & Kerry D Solomon. (2009) Ketorolac tromethamine 0.4% to relieve eye pain and inflammation following cataract extraction and keratorefractive surgery. Expert Review of Ophthalmology 4:5, pages 461-468.
Read now
Read now
Helga P Sandoval, Luis E Fernández de Castro, David T Vroman & Kerry D Solomon. (2007) A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery. Clinical Ophthalmology 1:4, pages 367-371.
Read now
Read now
L. David Waterbury, David Silliman & Thierry Jolas. (2006) Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Current Medical Research and Opinion 22:6, pages 1133-1140.
Read now
Read now
Richard Lindstrom & Terry Kim. (2006) Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Current Medical Research and Opinion 22:2, pages 397-404.
Read now
Read now
Henry D Perry & Eric D Donnenfeld. (2006) An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opinion on Pharmacotherapy 7:1, pages 99-107.
Read now
Read now
Articles from other publishers (26)
Shiva Taghe, Shahla Mirzaeei & Masood Bagheri. (2024) Preparation of polycaprolactone and polymethacrylate nanofibers for controlled ocular delivery of ketorolac tromethamine: Pharmacokinetic study in Rabbit's Eye. European Journal of Pharmaceutical Sciences 192, pages 106631.
Crossref
Crossref
Ghobad Mohammadi, Shahla Mirzaeei, Shiva TaghePardis Mohammadi. (2019) Preparation and Evaluation of Eudragit® L100 Nanoparticles LoadedImpregnated with KT Tromethamine Loaded PVA -HEC Insertions forOphthalmic Drug Delivery. Advanced Pharmaceutical Bulletin 9:4, pages 593-600.
Crossref
Crossref
Nathan A. Cleaveland, Derek W. De Mann, Neil E. Carlson & Michael L. Keil. (2017) Efficacy and perioperative timing of bromfenac in the management of ocular discomfort after femtosecond laser–assisted laser in situ keratomileusis. Journal of Cataract and Refractive Surgery 43:2, pages 183-188.
Crossref
Crossref
Yong Koo Kang, Myung Jun Kim, Hong Kyun Kim & Bo Young Chun. (2017) Clinical Analysis of Ocular Parameters Contributing to Intraoperative Pain during Standard Phacoemulsification. Journal of Ophthalmology 2017, pages 1-5.
Crossref
Crossref
Salim Ben Yahia, Rim Kahloun, Nesrine Abroug, Imene Kaibi, Ghassen Laadhari, Bechir Jelliti & Moncef Khairallah. (2016) Comparative effect of topical diclofenac and topical dexamethasone on anterior chamber flare and postoperative pain following rhegmatogenous retinal detachment surgery. International Ophthalmology 36:5, pages 623-628.
Crossref
Crossref
Susanna Porela-Tiihonen, Hannu Kokki, Kai Kaarniranta & Merja Kokki. (2016) Recovery after cataract surgery. Acta Ophthalmologica 94, pages 1-34.
Crossref
Crossref
Afshin ShafieeLyle M. BowmanEddie HouKamran Hosseini. (2013) Aqueous Humor Penetration of Ketorolac Formulated in DuraSite or DuraSite 2 Delivery Systems Compared to Acular LS in Rabbits. Journal of Ocular Pharmacology and Therapeutics 29:9, pages 812-816.
Crossref
Crossref
Constantine D. GeorgakopoulosPanagiotis T. VasilakisOlga E. MakriEleni BeredimaNikolaos M. Pharmakakis. (2012) Effect of Ketorolac 0.5% Drops on Patients' Pain Perception During Intravitreal Injection Procedure. Journal of Ocular Pharmacology and Therapeutics 28:5, pages 455-458.
Crossref
Crossref
Frank A. BucciJr.Jr. & L. David Waterbury. (2011) Prostaglandin E2 Inhibition of Ketorolac 0.45%, Bromfenac 0.09%, and Nepafenac 0.1% in Patients Undergoing Phacoemulsification. Advances in Therapy 28:12, pages 1089-1095.
Crossref
Crossref
Carmen Giannantonio, Patrizia Papacci, Velia Purcaro, Francesco Cota, Mikael Ghennet Tesfagabir, Fernando Molle, Domenico Lepore, Antonio Baldascino & Costantino Romagnoli. (2011) Effectiveness of Ketorolac Tromethamine in Prevention of Severe Retinopathy of Prematurity. Journal of Pediatric Ophthalmology & Strabismus 48:4, pages 247-251.
Crossref
Crossref
Eric D. Donnenfeld, Louis D. Nichamin, David R. Hardten, Michael B. Raizman, William Trattler, Rajesh K. Rajpal, Louis M. Alpern, Carlos Felix, Ronald R. Bradford, Linda Villanueva, David A. Hollander & Rhett M. Schiffman. (2011) Twice-Daily, Preservative-Free Ketorolac 0.45% for Treatment of Inflammation and Pain After Cataract Surgery. American Journal of Ophthalmology 151:3, pages 420-426.e1.
Crossref
Crossref
Stephen J. Kim, Allan J. Flach & Lee M. Jampol. (2010) Nonsteroidal Anti-inflammatory Drugs in Ophthalmology. Survey of Ophthalmology 55:2, pages 108-133.
Crossref
Crossref
Joana Araújo, Elisabet Gonzalez, Maria Antonia Egea, Marisa Luisa Garcia & Eliana B. Souto. (2009) Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine: Nanotechnology, Biology and Medicine 5:4, pages 394-401.
Crossref
Crossref
Frank A. BucciJr.Jr. & L. David Waterbury. (2009) Aqueous prostaglandin E2 of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing. Advances in Therapy 26:6, pages 645-650.
Crossref
Crossref
Paul J. Dougherty. (2009) Acular LS Before and During LASIK for the Control of Pain: A Randomized, Masked Contralateral Eye Trial. Journal of Refractive Surgery 25:2, pages 210-213.
Crossref
Crossref
Ana Munoz Morales, Muhamet Kivilcim, Muhammad Main, Gholam A. Peyman & Roberta Pereira de Almada Manzano. (2009) Intravitreal Toxicity of Ketorolac Tris Salt and Flurbiprofen. Ophthalmic Surgery, Lasers and Imaging Retina 40:1, pages 38-42.
Crossref
Crossref
W. Andrew MaxwellHarvey J. ReiserRobert H. StewartH. Dwight CavanaghThomas R. WaltersDana P. SagerPatricia A. Meuse. (2008) Nepafenac Dosing Frequency for Ocular Pain and Inflammation Associated with Cataract Surgery. Journal of Ocular Pharmacology and Therapeutics 24:6, pages 593-600.
Crossref
Crossref
Frank A. Bucci & David L. Waterbury. (2008) Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: Aqueous drug absorption and prostaglandin E2 levels. Journal of Cataract and Refractive Surgery 34:9, pages 1509-1512.
Crossref
Crossref
Hon-Vu Q. Duong, Kenneth C. Westfield & Thomas H.F. Chalkley. (2007) Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Journal of Cataract and Refractive Surgery 33:11, pages 1925-1929.
Crossref
Crossref
Tom Walters, Michael Raizman, Paul Ernest, Johnny Gayton & Robert Lehmann. (2007) In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. Journal of Cataract and Refractive Surgery 33:9, pages 1539-1545.
Crossref
Crossref
William Trattler & Marguerite McDonald. (2007) Double-Masked Comparison of Ketorolac Tromethamine 0.4% Versus Nepafenac Sodium 0.1% for Postoperative Healing Rates and Pain Control in Eyes Undergoing Surface Ablation. Cornea 26:6, pages 665-669.
Crossref
Crossref
Joseph Colin. (2007) The Role of NSAIDs in the Management of Postoperative Ophthalmic Inflammation. Drugs 67:9, pages 1291-1308.
Crossref
Crossref
Haluk EsginHasan Semih Samut. (2006) Topical Ketorolac 0.5% for Ocular Pain Relief During Scatter Laser Photocoagulation with 532 nm Green Laser. Journal of Ocular Pharmacology and Therapeutics 22:6, pages 460-464.
Crossref
Crossref
Eric D. Donnenfeld, Henry D. Perry, John R. Wittpenn, Renée Solomon, Alanna Nattis & Timothy Chou. (2006) Preoperative ketorolac tromethamine 0.4% in phacoemulsification outcomes: Pharmacokinetic-response curve. Journal of Cataract and Refractive Surgery 32:9, pages 1474-1482.
Crossref
Crossref
Helga P. SandovalLuis E. Fernández De CastroDavid T. VromanKerry D. Solomon. (2006) Evaluation of 0.4% Ketorolac Tromethamine Ophthalmic Solution Versus 0.5% Ketorolac Tromethamine Ophthalmic Solution After Phacoemulsification and Intraocular Lens Implantation. Journal of Ocular Pharmacology and Therapeutics 22:4, pages 251-257.
Crossref
Crossref
Barry A. Schechter. (2006) Ketorolac During the Induction Phase of Cyclosporin-A Therapy. Journal of Ocular Pharmacology and Therapeutics 22:2, pages 150-154.
Crossref
Crossref